157 related articles for article (PubMed ID: 35726954)
1. Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis.
Shopsowitz KE; Liu L; Setiadi A; Al-Bakri M; Vercauteren S
Cytometry B Clin Cytom; 2022 Sep; 102(5):342-352. PubMed ID: 35726954
[TBL] [Abstract][Full Text] [Related]
2. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
3. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
[TBL] [Abstract][Full Text] [Related]
4. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
Shaver AC; Seegmiller AC
Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
6. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
Cherian S; Soma LA
Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
[TBL] [Abstract][Full Text] [Related]
7. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
8. A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.
Keeney M; Wood BL; Hedley BD; DiGiuseppe JA; Stetler-Stevenson M; Paietta E; Lozanski G; Seegmiller AC; Greig BW; Shaver AC; Mukundan L; Higley HR; Sigman CC; Kelloff G; Jessup JM; Borowitz MJ
Cytometry B Clin Cytom; 2018 Mar; 94(2):239-249. PubMed ID: 28475275
[TBL] [Abstract][Full Text] [Related]
9. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
Chen X; Gao Q; Roshal M; Cherian S
Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
[TBL] [Abstract][Full Text] [Related]
11. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
12. Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.
Borowitz MJ; Wood BL; Keeney M; Hedley BD
Curr Protoc; 2022 Mar; 2(3):e383. PubMed ID: 35263042
[TBL] [Abstract][Full Text] [Related]
13. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
15. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
16. Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
Gupta S; Devidas M; Loh ML; Raetz EA; Chen S; Wang C; Brown P; Carroll AJ; Heerema NA; Gastier-Foster JM; Dunsmore KP; Larsen EC; Maloney KW; Mattano LA; Winter SS; Winick NJ; Carroll WL; Hunger SP; Borowitz MJ; Wood BL
Leukemia; 2018 Jun; 32(6):1370-1379. PubMed ID: 29472723
[TBL] [Abstract][Full Text] [Related]
17. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Vinhas E; Lucena-Silva N; Pedrosa F
Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
[TBL] [Abstract][Full Text] [Related]
20. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
